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1. INTRODUCTION {#dom13345-sec-0005}
===============

Current United States (US) guidelines recommend basal insulin therapy as an option for people with type 2 diabetes (T2D) that is uncontrolled using metformin with or without additional oral antidiabetic drugs.[1](#dom13345-bib-0001){ref-type="ref"}, [2](#dom13345-bib-0002){ref-type="ref"} Second‐generation basal insulin analogues (eg, insulin glargine 300 units/mL \[Gla‐300\][3](#dom13345-bib-0003){ref-type="ref"} and insulin degludec \[IDeg\][4](#dom13345-bib-0004){ref-type="ref"}) became available in the US in 2015. These have more stable pharmacokinetic and pharmacodynamic profiles and a longer duration of action than the first‐generation basal insulin analogues (eg, insulin glargine 100 units/mL \[Gla‐100\] or insulin detemir \[IDet\]).[5](#dom13345-bib-0005){ref-type="ref"}, [6](#dom13345-bib-0006){ref-type="ref"}

The EDITION clinical trial programme, which compared Gla‐300 with Gla‐100 in patients with diabetes, showed that Gla‐300 provides similar glycaemic control to Gla‐100, with less confirmed (≤3.9 mmol/L \[70 mg/dL\]) or severe hypoglycaemia, over a period of 6 months in patients with T2D.[7](#dom13345-bib-0007){ref-type="ref"} Similarly, the BEGIN clinical trial programme, which studied IDeg across the spectrum of diabetes, showed that IDeg was associated with reduced nocturnal confirmed hypoglycaemia when compared with Gla‐100 in patients with T2D.[6](#dom13345-bib-0006){ref-type="ref"} Head‐to‐head comparisons between the second‐generation basal insulin analogues are limited to euglycaemic clamp studies. While one euglycaemic clamp study demonstrated a favourable pharmacokinetic and pharmacodynamic profile with IDeg,[8](#dom13345-bib-0008){ref-type="ref"} another has reported that, compared with IDeg, Gla‐300 offers a more even pharmacokinetic and pharmacodynamic profile when used in patients with type 1 diabetes (T1D)[9](#dom13345-bib-0009){ref-type="ref"}; however, no comparative efficacy data comparing the second‐generation basal insulin analogues are available, although 2 head‐to‐head randomized controlled trials (RCTs) comparing Gla‐300 and IDeg are currently underway.[10](#dom13345-bib-0010){ref-type="ref"}, [11](#dom13345-bib-0011){ref-type="ref"}

Growing interest in comparative effectiveness research[12](#dom13345-bib-0012){ref-type="ref"} and an increasing demand for real‐world data[13](#dom13345-bib-0013){ref-type="ref"} to support clinical decision‐making have established a need for, and highlighted the importance of, the inclusion of non‐RCT data sources (electronic medical records \[EMRs\], electronic registries, etc.) in clinical studies. For example, the outcomes of switching from first‐generation to second‐generation basal insulin analogues in patients with T2D in routine real‐world clinical practice settings have been studied in the Differentiate Gla‐300 clinical and Economic in reaL‐world Via EMR (DELIVER) studies. DELIVER 2 (in patients aged ≥18 years)[14](#dom13345-bib-0014){ref-type="ref"} and DELIVER 3 (in patients aged ≥65 years)[15](#dom13345-bib-0015){ref-type="ref"} included patients with T2D who switched from basal insulin to Gla‐300 or another basal insulin (IDet, Gla‐100, or IDeg); DELIVER D included adults with T2D who switched from Gla‐100 to Gla‐300 or IDeg.[16](#dom13345-bib-0016){ref-type="ref"}

In the present paper, we report the methods and results from DELIVER D+, a real‐world study that included adults with T2D who switched from Gla‐100 or IDet to either Gla‐300 or IDeg. The objective of this study was to compare clinical outcomes (glycated haemoglobin \[HbA1c\] reduction, HbA1c goal attainment, and hypoglycaemia) for the 2 second‐generation basal insulin analogues in patients receiving care in real‐world clinical practice settings. The outcomes were also evaluated in five subgroups of patients known to potentially have increased risk of hypoglycaemia.

2. MATERIALS AND METHODS {#dom13345-sec-0006}
========================

2.1. Study design and data source {#dom13345-sec-0007}
---------------------------------

DELIVER D+ was a retrospective cohort study covering the period March 1, 2014 to July 31, 2017. Data were obtained from the Predictive Health Intelligence Environment database (IBM Explorys, Cleveland, Ohio), which provides real‐world, real‐time EMR data for \~18% of the US population from 39 integrated healthcare systems. It captures \>315 billion clinical, financial, and operational data elements, spanning 55 million unique patients, 420 hospitals and \>400 000 providers. Data (demographics, diagnoses, treatment, laboratory results, encounter‐level data, etc.) were standardized and normalized using common ontologies. Data from multiple health systems (inpatient, outpatient, emergency, ambulatory, etc.) were available, with a combination of data from clinical EMRs, healthcare system outgoing bills, and adjudicated payer claims.

2.2. Study population {#dom13345-sec-0008}
---------------------

Adult patients (aged ≥18 years) with T2D (≥1 diagnosis according to International Classification of Diseases version 9 or 10 \[ICD‐9/ICD‐10\] codes[17](#dom13345-bib-0017){ref-type="ref"} ever in the EMR database) who switched from either Gla‐100 or IDet to either Gla‐300 or IDeg during the identification period (March 1, 2015 to January 31, 2017) were included. The date of first prescription of Gla‐300 or IDeg (index basal insulin) in the EMR during the identification period was defined as the index date.

To be included in the cohort, patients had to be active in the EMR system for ≥12 months before the index date (12‐month baseline) and have ≥6 months of follow‐up data after the index date. Patients must have been treated with one basal insulin (Gla‐100 or IDet) and have ≥1 valid HbA1c measure (HbA1c 3% \[9 mmol/mol\]--15% \[140 mmol/mol\]) obtained during the 6 months before the index date (6‐month baseline). Patients with T1D were excluded (see Table [S1](#dom13345-supitem-0001){ref-type="supplementary-material"} (Supporting Information) for the algorithm used to identify patients with T1D),[18](#dom13345-bib-0018){ref-type="ref"} as were those with a prescription for more than one basal insulin on the index date.

2.3. Outcomes {#dom13345-sec-0009}
-------------

Patients who switched from Gla‐100 or IDet to Gla‐300 ("Gla‐300 switchers") were compared with those who switched from Gla‐100 or IDet to IDeg ("IDeg switchers"). HbA1c reduction (baseline to follow‐up) and HbA1c goal attainment (\<7.0% \[53 mmol/mol\] and \<8.0% \[64 mmol/mol\]) were compared (Gla‐300 vs IDeg) for patients who had ≥1 valid HbA1c measure during 3 to 6 months of follow‐up. The last HbA1c value before the index date was used for the baseline HbA1c measurement. The last follow‐up HbA1c measurement (taken in the 3--6 months following the index date) was used.

Hypoglycaemia events (based on ICD‐9/ICD‐10 diagnoses or blood glucose ≤3.9 mmol/L \[70 mg/dL\] reported in the EMRs; both all hypoglycaemia events and those associated with an inpatient or emergency department \[ED\] encounter) were analysed for all patients.

Hypoglycaemia outcomes were assessed using two approaches: intention‐to‐treat (ITT; events were assessed over the full 6‐month follow‐up period) and on‐treatment (OT; events were captured during treatment; follow‐up was until the earlier of either discontinuation of index basal insulin or the end of the 6‐month follow‐up period). Treatment discontinuation was defined as switching to another basal insulin or having a prescription gap of \>45 days. The discontinuation date was the basal insulin switch date or the last prescription end date.

2.4. Propensity‐score matching {#dom13345-sec-0010}
------------------------------

To minimize confounding, patients were propensity‐score‐matched[19](#dom13345-bib-0019){ref-type="ref"}, [20](#dom13345-bib-0020){ref-type="ref"}, [21](#dom13345-bib-0021){ref-type="ref"} (1:1) based on baseline demographics and clinical characteristics using a "greedy nearest neighbour" algorithm. Propensity scores were matched from 2 decimal places to up to 8 decimal places. This selects a patient treated with IDeg, and then selects a patient treated with Gla‐300 with the closest propensity score. Once matched, patients were not reconsidered.

Baseline characteristics used for matching included: age; gender; body mass index; race; insurance type; US geographic region; HbA1c; hypoglycaemia; healthcare resource use; comorbidities (Elixhauser comorbidity index)[22](#dom13345-bib-0022){ref-type="ref"} and diabetic complications; antidiabetic injectable use (glucagon‐like peptide 1 receptor agonist, rapid‐acting insulin); baseline basal insulin; oral antidiabetic drug use; and concomitant medication use. Medication use and comorbidities were captured during the 12‐month baseline period; HbA1c and hypoglycaemia events were captured during the 6‐month baseline period. To assess imbalance in individual baseline characteristics, χ^2^/2‐sample *t* tests were performed and the standardized mean difference was calculated.

2.5. Statistical analysis {#dom13345-sec-0011}
-------------------------

Categorical variables are presented as frequencies and percentages and continuous variables as means ± standard deviation (SD).

Reductions in HbA1c and HbA1c goal attainment were assessed for matched patients with ≥1 HbA1c measure during both 6‐month baseline and 3 to 6‐month follow‐up. HbA1c comparison between baseline and follow‐up within each cohort was tested using paired *t* tests. HbA1c reduction from baseline was compared between cohorts using a 2‐sample *t* test. χ^2^ tests were used to assess differences between the two cohorts in the proportion of patients who reached pre‐specified HbA1c targets within the 6‐month follow‐up period.

Hypoglycaemia incidence using 6‐month fixed follow‐up (ITT) is reported as the percentages of patients with ≥1 event in the two cohorts. Odds ratios, adjusted for baseline hypoglycaemia incidence, were calculated to compare the risk of hypoglycaemia between the two cohorts using logistic regression. Hypoglycaemia event rates using ITT are reported as events per person per year. Adjusted least squares mean differences were calculated for hypoglycaemia event rates in the two cohorts; these were controlled for baseline hypoglycaemia events using a generalized linear model procedure. Hypoglycaemia incidences at follow‐up were compared with baseline incidences for both cohorts using McNemar\'s test.

Hypoglycaemia incidence using variable follow‐up (OT) was calculated as the number of patients experiencing a first hypoglycaemia event divided by the total follow‐up to first event (incidence per person‐years). Hazard ratios adjusted for baseline hypoglycaemia incidence (determined using a proportional hazard Cox model) were calculated to compare hypoglycaemia incidence risk when receiving treatment for the two cohorts. Hypoglycaemia event rates using variable follow‐up (OT) were calculated as number of events divided by the total follow‐up to discontinuation of index basal insulin or the end of the 6‐month follow‐up (events per person‐year). Adjusted rate ratios (adjusted for baseline hypoglycaemia events using Poisson regression) were calculated to compare hypoglycaemia events in the 2 cohorts.

2.6. Sensitivity analyses {#dom13345-sec-0012}
-------------------------

Sensitivity analyses for the HbA1c and hypoglycaemia outcomes were conducted by changing the patient identification period to December 1, 2015 to January 31, 2017, a period during which both second‐generation basal insulin analogues were commercially available in the US. Sensitivity analyses for the HbA1c outcome were also conducted by limiting eligible patients to those who did not discontinue index basal insulin treatment within 75 days of the index date.

2.7. Subgroup analyses {#dom13345-sec-0013}
----------------------

The following subgroups were explored to compare clinical outcomes in various sub‐populations of interest:patients taking a combination of basal and prandial (both rapid‐acting and short‐acting) insulins: (1) ≥1 new prescription of prandial insulin during the 6‐month baseline period (ie, treatment was initiated within the 6 months before the index date) or (2) a prescription with an end date during 6‐month baseline (ie, a prescription showing the patient was still being treated with a prandial insulin during the 6‐month baseline period);patients with moderate or severe renal impairment (estimated glomerular filtration rate \<60 mL/min/1.73 m^2^ or nephropathy diagnosis);patients with baseline HbA1c ≥8.0%;patients at high hypoglycaemia risk (proxy to SWITCH 2 trial),[23](#dom13345-bib-0023){ref-type="ref"} characterized by at least one of the following: (1) ≥1 severe hypoglycaemic (inpatient/ED) episode within the 12‐month baseline period; (2) moderate renal impairment (estimated glomerular filtration rate 30--59 mL/min/1.73 m^2^); and (3) exposure to insulin for \>4 years; (4) recent episode of hypoglycaemia (ICD diagnosis and/or glucose ≤3.9 mmol/L \[70 mg/dL\] within 12 weeks of baseline);adults aged ≥65 years.

Hypoglycaemia and HbA1c outcomes using fixed follow‐up (ITT) were compared for Gla‐300 vs IDeg switchers in all subgroups.

3. RESULTS {#dom13345-sec-0014}
==========

3.1. Patient selection and matching {#dom13345-sec-0015}
-----------------------------------

The study flow diagram is shown in Figure [1](#dom13345-fig-0001){ref-type="fig"}. A total of 3823 Gla‐300 switchers and 1699 IDeg switchers were eligible for inclusion in the study. After propensity‐score matching, there were 1592 patients in each cohort. The outcomes of HbA1c control (HbA1c reduction and goal attainment) were analysed in matched patients who had HbA1c measurements at baseline and at 3 to 6‐months\' follow‐up (742 and 727 in matched Gla‐300 and IDeg cohorts, respectively). The outcomes of hypoglycaemia were analysed in 1592 patients in each group.

![Patient flow chart. EMR, electronic medical records; Gla‐100, insulin glargine 100 units/mL; Gla‐300, insulin glargine 300 units/mL; HbA1c, haemoglobin A1c; IDeg, insulin degludec; IDet, insulin detemir; T1D, type 1 diabetes; T2D, type 2 diabetes. ^†^See Table [S1](#dom13345-supitem-0001){ref-type="supplementary-material"} for the conditions used to identify patients with T1D](DOM-20-2148-g001){#dom13345-fig-0001}

3.2. Baseline characteristics {#dom13345-sec-0016}
-----------------------------

Prior to propensity‐score matching, there were some differences between the two cohorts, mainly related to race, insurance type, geographic region and baseline basal insulin (significantly more patients among the Gla‐300 switchers were previously taking Gla‐100 than among the IDeg switchers \[77.3% vs 60.9%; *P* \< .001\]; Table [S2](#dom13345-supitem-0001){ref-type="supplementary-material"}, Supporting Information). There was, however, little difference in the rate of hypoglycaemia within the 6 months prior to the index date (15.7% of Gla‐300 switchers and 14.2% of IDeg switchers (*P* = .170) and the incidence rates of various cardiovascular diseases were also similar in the two groups (Table [S2](#dom13345-supitem-0001){ref-type="supplementary-material"}, Supporting Information). Any baseline differences were ameliorated after matching (Table [1](#dom13345-tbl-0001){ref-type="table"}). In the matched cohorts, the mean age was 59 years and \~50% of patients were men. Approximately 64% of patients in each group had switched from Gla‐100.

###### 

Baseline patient characteristics after propensity score matching

  ------------------------------------------------------------------------------------------------------------------------------------
                                                                                 Gla‐300 switchers\   IDeg switchers\   SMD    *P*
                                                                                 (*n* = 1592)         (*n* = 1592)             
  ------------------------------------------------------------------------------ -------------------- ----------------- ------ -------
  Age, years                                                                     59.0 ± 12.2          58.7 ± 12.7       0.02   .552

  Men, *n* (%)                                                                   805 (50.6)           781 (49.1)        0.03   .547

  Body mass index, kg/m^2^                                                       34.8 ± 7.4           34.7 ± 7.4        0.02   .616

  Race, *n* (%)                                                                                                                

  Caucasian                                                                      1192 (74.9)          1220 (76.6)       0.04   .569

  African American                                                               215 (13.5)           213 (13.4)        0.00   .923

  Other                                                                          92 (5.8)             92 (5.8)          0.00   1.000

  Unknown                                                                        93 (5.8)             67 (4.2)          0.07   .040

  Insurance type, *n* (%)                                                                                                      

  Commercial                                                                     651 (40.9)           669 (42.0)        0.02   .620

  Medicare                                                                       410 (25.8)           415 (26.1)        0.01   .862

  Medicaid                                                                       87 (5.5)             89 (5.6)          0.01   .880

  Other                                                                          76 (4.8)             77 (4.8)          0.00   .936

  Unknown                                                                        368 (23.1)           342 (21.5)        0.04   .329

  US geographic region, *n* (%)                                                                                                

  Midwest                                                                        882 (55.4)           877 (55.1)        0.01   .905

  South                                                                          615 (38.6)           612 (38.4)        0.00   .932

  West                                                                           65 (4.1)             64 (4.0)          0.00   .930

  Northeast                                                                      30 (1.9)             39 (2.4)          0.04   .279

  HbA1c, %                                                                       9.1 ± 1.9            9.1 ± 1.8         0.00   .915

  Body mass index, kg/m^2^                                                       34.9 ± 7.4           34.7 ± 7.4        0.02   .616

  Hypoglycaemia incidence in the 6 months prior to the index date, *n* (%)       249 (15.6)           227 (14.3)        0.04   .313

  Comorbidities, *n* (%)                                                                                                       

  Hyperlipidaemia                                                                1283 (80.6)          1295 (81.3)       0.02   .813

  Hypertension                                                                   1252 (78.6)          1253 (78.7)       0.00   .984

  Obesity                                                                        633 (39.8)           615 (38.6)        0.02   .610

  Neuropathy                                                                     472 (29.6)           477 (30.0)        0.01   .871

  Depression                                                                     293 (18.4)           285 (17.9)        0.01   .739

  Congestive heart failure                                                       180 (11.3)           166 (10.4)        0.04   .452

  Retinopathy                                                                    174 (10.9)           187 (11.7)        0.03   .494

  Nephropathy                                                                    152 (9.5)            148 (9.3)         0.01   .817

  Peripheral vascular disease                                                    150 (9.4)            138 (8.7)         0.02   .480

  Myocardial infarction                                                          100 (6.3)            75 (4.7)          0.05   .059

  Dementia                                                                       21 (1.3)             13 (0.8)          0.05   .170

  Stroke                                                                         8 (0.5)              5 (0.3)           0.06   .405

  Elixhauser comorbidities index score[22](#dom13345-bib-0022){ref-type="ref"}   3.7 ± 2.4            3.8 ± 2.5         0.04   .217

  Treatments in 12 months prior to index date, *n* (%)                                                                         

  Injectables                                                                                                                  

  Glucagon‐like peptide 1 receptor agonist                                       286 (18.0)           265 (16.7)        0.03   .371

  Rapid‐acting insulin                                                           883 (55.5)           859 (54.0)        0.03   .565

  Oral antidiabetic drugs                                                                                                      

  Number                                                                         1.1 ± 0.8            1.1 ± 0.8         0.01   .791

  Metformin, *n* (%)                                                             727 (45.7)           725 (45.5)        0.00   .958

  Sulphonylureas, *n* (%)                                                        382 (24.0)           373 (23.4)        0.01   .743

  Dipeptidyl peptidase‐4, *n* (%)                                                279 (17.5)           288 (18.1)        0.01   .705

  Sodium‐glucose co‐transporter‐2 inhibitors, *n* (%)                            204 (12.8)           225 (14.1)        0.04   .311

  Thiazolidinediones, *n* (%)                                                    74 (4.7)             62 (3.9)          0.04   .303

  Meglitinides, *n* (%)                                                          12 (0.8)             15 (0.9)          0.02   .564

  α‐glucosidase, *n* (%)                                                         2 (0.1)              7 (0.4)           0.06   .096

  Other concomitant drugs, *n* (%)                                                                                             

  Statins                                                                        1039 (65.3)          1072 (67.3)       0.04   .473

  ACE inhibitors                                                                 679 (42.7)           664 (41.7)        0.02   .682

  Beta‐blockers                                                                  453 (28.5)           432 (27.1)        0.03   .480

  Angiotensin receptor blockers                                                  172 (10.8)           174 (10.9)        0.00   .914

  Calcium channel blockers                                                       148 (9.3)            156 (9.8)         0.02   .646

  Diuretics                                                                      86 (5.4)             87 (5.5)          0.00   .939

  Healthcare utilization incidence in 6 months prior to index date, *n* (%)                                                    

  Inpatient incidence                                                            229 (14.4)           220 (13.8)        0.02   .671

  ED incidence                                                                   391 (24.6)           402 (25.3)        0.02   .696

  Endocrinological outpatient incidence                                          324 (20.4)           316 (19.9)        0.01   .752

  Baseline basal insulin, *n* (%)                                                                                              

  Gla‐100                                                                        1018 (63.9)          1013 (63.6)       0.01   .912

  IDet                                                                           574 (36.1)           579 (36.4)        0.01   .883
  ------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ACE, angiotensin‐converting enzyme; ED, emergency department; Gla‐100, insulin glargine 100 units/mL; Gla‐300, insulin glargine 300 units/mL; HbA1c, glycated haemoglobin; IDeg, insulin degludec; IDet, insulin detemir; SMD, standardized mean difference. Data are presented as mean ± SD unless otherwise indicated.

3.3. HbA1c control {#dom13345-sec-0017}
------------------

The mean HbA1c reductions among patients with both baseline and follow‐up HbA1c measurements were similar in the Gla‐300 and IDeg cohorts (0.63 ± 1.7% and 0.58 ± 1.6%, respectively; *P* = .488). The mean HbA1c decreased significantly from baseline to follow‐up in both cohorts (*P* \< .001; Figure [2](#dom13345-fig-0002){ref-type="fig"}A). Patients in both cohorts were equally likely to attain the HbA1c targets of \<7.0% (53 mmol/mol) and \<8.0% (64 mmol/mol) (Figure [2](#dom13345-fig-0002){ref-type="fig"}B).

![Glycated haemoglobin (HbA1c) outcomes among matched patients with HbA1c test results during baseline (0‐6 months prior to the index date) and follow‐up (3‐6 months after the index date): (A) mean ± SD values during baseline and follow‐up; (B) attainment of goals (\<7.0% \[53 mmol/mol\] and \<8.0% \[64 mmol/mol\]). Gla‐300, insulin glargine 300 units/mL; IDeg, insulin degludec](DOM-20-2148-g003){#dom13345-fig-0002}

3.4. Hypoglycaemia {#dom13345-sec-0018}
------------------

Using fixed follow‐up to 6 months (ITT), the hypoglycaemia incidence rates (Figure [3](#dom13345-fig-0003){ref-type="fig"}A) and the adjusted hypoglycaemia event rates (Figure [3](#dom13345-fig-0003){ref-type="fig"}B) were similar for Gla‐300 and IDeg switchers. This was also the case for hypoglycaemia associated with an inpatient/ED encounter (Figure [3](#dom13345-fig-0003){ref-type="fig"}C and 3D). The incidence rates for all and inpatient/ED hypoglycaemia decreased from baseline to follow‐up in both cohorts, but the differences were only significant for Gla‐300 switchers (Figure [3](#dom13345-fig-0003){ref-type="fig"}E).

![Hypoglycaemia outcomes among all matched patients during fixed 6‐month follow‐up: (A) incidence; (B) adjusted event rate; (C) inpatient/ emergency department (ED) hypoglycaemia incidence; (D) inpatient/ED hypoglycaemia adjusted event rate; (E) hypoglycaemia incidence decreases from baseline to follow‐up. aOR, odds ratio adjusted for baseline hypoglycaemia incidence; CI, confidence interval; Gla‐300, insulin glargine 300 units/mL; IDeg, insulin degludec; LSM, least squares mean; PPPY, per person per year. ^†^ *P* values adjusted for baseline hypoglycaemia incidence](DOM-20-2148-g002){#dom13345-fig-0003}

When splitting the follow‐up into 0 to 3 and 4 to 6 months (ie, titration and maintenance), there were no significant differences in hypoglycaemia outcomes between the two cohorts during either time period (Figure S1A‐D, Supporting Information).

In total, 32.0% and 28.5% of patients discontinued treatment in the Gla‐300 and IDeg cohorts, respectively, during 6‐month follow‐up. Using variable follow‐up (OT), there were no significant differences in hypoglycaemia crude incidence rate and hypoglycaemia event rate between the two cohorts, apart from a significantly lower inpatient/ED hypoglycaemic event rate in the Gla‐300 vs IDeg group after adjustment for baseline hypoglycaemia (Table [2](#dom13345-tbl-0002){ref-type="table"}).

###### 

Hypoglycaemia outcomes using variable (on‐treatment) follow‐up

                                           Hypoglycaemia   Inpatient/ED hypoglycaemia                                                                        
  ---------------------------------------- --------------- ---------------------------- ------------------- ------ ---------- ---------- ------------------- ------
  Patients with ≥1 event, *n* (%)          148 (9.3)       138 (8.7)                    --                  --     26 (1.6)   30 (1.9)   --                  --
  Follow‐up to first event, person‐years   557             572                          --                  --     585        598        --                  --
  Crude incidence rate, PPY                0.27            0.24                         1.02 (0.81--1.29)   .877   0.04       0.05       0.80 (0.47--1.36)   .417
  Events, *n*                              223             222                          --                  --     32         47         --                  --
  Total follow‐up, person‐years            589             603                          --                  --     589        603        --                  --
  Event rate, PPY                          0.38            0.37                         0.94 (0.78--1.14)   .558   0.05       0.08       0.56 (0.35--0.90)   .016

Abbreviations: aHR, hazard ratio adjusted for baseline hypoglycaemia incidence; aRR, rate ratio adjusted for baseline hypoglycaemia incidence; ED, emergency department; Gla‐300, insulin glargine 300 units/mL; IDeg, insulin degludec; PPY, per person‐year.

aHR for crude incidence rate (proportional hazard Cox model); aRR for event rate (Poisson regression).

*P* values adjusted for baseline hypoglycaemia incidence.

3.5. Sensitivity analyses {#dom13345-sec-0019}
-------------------------

Changing the identification period to December 1, 2015 to January 31, 2017 (when both products were commercially available to patients) resulted in 2699 and 1699 patients in the unmatched populations, 1520 and 1520 patients in the matched populations, and 700 and 695 patients with follow‐up HbA1c for Gla‐300 and IDeg switchers, respectively. HbA1c reduction results were consistent with the main analysis, with similar reductions being observed in Gla‐300 and IDeg switchers (−0.72 ± 1.75% and −0.58 ± 1.57%, respectively; *P* = .120). HbA1c goal results were also similar to the main results (\<7.0% \[53 mmol/mol\]: 17.1% vs 16.0%; *P* = .565 and \<8.0% \[64 mmol/mol\]: 46.6% vs 44.6%; *P* = .485 for Gla‐300 vs IDeg switchers, respectively), as were hypoglycaemia incidence and event rate results (using both ITT and OT methods).

For patients who continued treatment for ≥75 days and had follow‐up HbA1c (Gla‐300, *n* = 569; IDeg, *n* = 572), HbA1c reduction (0.64 ± 1.70% and 0.57 ± 1.52%, for Gla‐300 and IDeg, respectively; *P* = .428) and goal attainment, results were also similar to the main results.

3.6. Subgroup analyses {#dom13345-sec-0020}
----------------------

Despite some variation in the magnitude of HbA1c reduction in the various subgroups (HbA1c reduction was greatest in those patients with HbA1c ≥8.0% (64 mmol/mol) at baseline, for example), there were no significant differences when comparing HbA1c reductions for Gla‐300 vs IDeg switchers in each of the subgroups (Figure S2A, Supporting Information). With respect to hypoglycaemia incidence (and although incidence was highest among those at high hypoglycaemia risk and those with moderate/severe renal impairment), there were no significant differences when comparing hypoglycaemia incidence for Gla‐300 vs IDeg switchers in each of the subgroups (Figure S2B, Supporting Information).

4. DISCUSSION {#dom13345-sec-0021}
=============

In the absence of head‐to‐head trials comparing Gla‐300 and IDeg, DELIVER D+ provides the first comparative evidence on clinical outcomes when switching from Gla‐100/IDet to Gla‐300 or IDeg. In this real‐world study, adults with T2D who switched from first‐generation to second‐generation basal insulin analogues (Gla‐300 or IDeg) achieved similar reductions in HbA1c. This was also found in the DELIVER D study, in which patients switched solely from Gla‐100 to Gla‐300 or IDeg.[16](#dom13345-bib-0016){ref-type="ref"}

Patients in both DELIVER D+ cohorts achieved significant reductions in HbA1c levels vs baseline. This is in line with DELIVER D,[16](#dom13345-bib-0016){ref-type="ref"} DELIVER 2,[14](#dom13345-bib-0014){ref-type="ref"} and three other observational studies, in which patients with T2D switched mainly from Gla‐100 or IDet to Gla‐300 (US study)[24](#dom13345-bib-0024){ref-type="ref"} or from Gla‐100 or IDet to IDeg (European[25](#dom13345-bib-0025){ref-type="ref"} and Japanese[26](#dom13345-bib-0026){ref-type="ref"} studies). These three studies reported significant reductions in HbA1c after switching. The results are also in line with RCTs including EDITION 1, 2 and JP 2 (Gla‐300)[27](#dom13345-bib-0027){ref-type="ref"}, [28](#dom13345-bib-0028){ref-type="ref"}, [29](#dom13345-bib-0029){ref-type="ref"} and BEGIN (IDeg).[30](#dom13345-bib-0030){ref-type="ref"}

As in DELIVER D,[16](#dom13345-bib-0016){ref-type="ref"} achievement of HbA1c targets in DELIVER D+ was similar for Gla‐300 and IDeg switchers; however, only \~15% of patients achieved HbA1c \<7.0%. This is lower than was achieved with Gla‐300 in EDITION 1, 2 and JP 2 at 6 months (25%--40%)[27](#dom13345-bib-0027){ref-type="ref"}, [28](#dom13345-bib-0028){ref-type="ref"}, [29](#dom13345-bib-0029){ref-type="ref"} and with IDeg in BEGIN at 12 months (49%).[30](#dom13345-bib-0030){ref-type="ref"}

There are several possible explanations for this: (1) DELIVER D+ examined EMRs of real‐world patients, while in the RCTs, the dose was titrated to target (fasting plasma glucose 4.4--5.6 mmol/L[27](#dom13345-bib-0027){ref-type="ref"}, [28](#dom13345-bib-0028){ref-type="ref"}, [29](#dom13345-bib-0029){ref-type="ref"} or 3.9--\<5.0 mmol/L[30](#dom13345-bib-0030){ref-type="ref"}), indicating that real‐world treatment may not be sufficiently intensified, or that glucose targets are higher in some patients; (2) in the RCTs, close monitoring could have improved adherence; (3) mean baseline HbA1c was higher in DELIVER D+ than in the RCTs, which can be associated with poorer target achievement; and (4) in real‐world use, patients may switch therapies because of poor glycaemic control (and indeed have higher mean HbA1c levels than those seen in the RCTs studying second‐generation basal insulin analogues), which could select patients less likely to achieve glycaemic targets.

The incidicence of hypoglycaemia at follow‐up was largely similar for Gla‐300 vs IDeg switchers; however, using the fixed follow‐up (ITT) method, hypoglycaemia incidence (all and inpatient/ED) reduced significantly from baseline to follow‐up in Gla‐300 switchers; the decreases were not significant for IDeg switchers. When using the variable follow‐up (OT) method and adjusting for baseline hypoglycaemia, Gla‐300 switchers had a significantly lower inpatient/ED hypoglycaemia event rate than IDeg switchers.

In DELIVER D, hypoglycaemia outcomes were similar for Gla‐300 vs IDeg switchers.[16](#dom13345-bib-0016){ref-type="ref"} In DELIVER 2 and 3, there was significantly less hypoglycaemia in patients who switched to Gla‐300 vs other basal insulins,[14](#dom13345-bib-0014){ref-type="ref"}, [15](#dom13345-bib-0015){ref-type="ref"} probably because the "other basal insulin" group mainly included patients treated with first‐generation basal insulin analogues. Overall, the results from the DELIVER studies support reduced hypoglycaemia incidence with second‐generation basal insulin analogues.

Various other studies have also reported reduced hypoglycaemia incidence when switching to second‐generation basal insulin analogues. In the above‐mentioned observational studies (from the US, Europe and Japan), switching to Gla‐300[24](#dom13345-bib-0024){ref-type="ref"} or IDeg[25](#dom13345-bib-0025){ref-type="ref"}, [26](#dom13345-bib-0026){ref-type="ref"} resulted in significant reductions in hypoglycaemia event rates. The improvement in hypoglycaemia with Gla‐300 is also supported by data from the EDITION studies, which reported significantly lower confirmed or severe nocturnal hypoglycaemia in patients randomized to Gla‐300 vs Gla‐100.[27](#dom13345-bib-0027){ref-type="ref"}, [28](#dom13345-bib-0028){ref-type="ref"}, [29](#dom13345-bib-0029){ref-type="ref"} Both the BEGIN and SWITCH 2 studies reported significantly reduced hypoglycaemia in patients randomized to IDeg vs Gla‐100,[23](#dom13345-bib-0023){ref-type="ref"}, [30](#dom13345-bib-0030){ref-type="ref"} and the DEVOTE trial also reported less adjudicated severe hypoglycaemia in patients using IDeg vs Gla‐100 in a longer 2‐year follow‐up.[31](#dom13345-bib-0031){ref-type="ref"} This reduced risk of hypoglycaemia with the second‐generation basal insulin analogues may help reduce barriers for basal insulin use,[32](#dom13345-bib-0032){ref-type="ref"} improve adherence,[33](#dom13345-bib-0033){ref-type="ref"}, [34](#dom13345-bib-0034){ref-type="ref"} and reduce hypoglycaemia‐related healthcare resource utilization and associated costs[14](#dom13345-bib-0014){ref-type="ref"}; further studies could provide evidence related to these possibilities.

Overall, DELIVER D+ reported that switching from a first‐generation (Gla‐100 or IDet) to a second‐generation (Gla‐300 or IDeg) basal insulin analogue resulted in post‐switch improvements in glycaemic control and hypoglycaemia incidence that were similar for Gla‐300 vs IDeg. These results were consistent among various subgroups of interest, including those with uncontrolled HbA1c, renal impairment and high hypoglycaemia risk (proxy SWITCH 2 trial criteria), and the elderly. Using proxy definitions of RCTs for selecting patients with high hypoglycaemia risk, the similar improvement in incidence and rates of hypoglycaemia compared with RCTs shows that the 2 second‐generation basal insulin analogues have similar clinical outcomes in high‐risk patients with T2D in real‐world practice. Second‐generation basal insulin analogue use may be especially advantageous in certain subgroups of patients who may derive particular benefit from a more stable insulin action and a reduced risk of hypoglycaemia.

In this real‐world study, each subgroup accounted for \~30% to 70% of the overall population. Many of the patients in the subgroups would probably be excluded from RCTs. This has been recognized by Saunders et al.,[35](#dom13345-bib-0035){ref-type="ref"} who reported that only \~5% to 50% of people with T2D would have been eligible for the various RCTs that have assessed the impact of glycaemic control on macrovascular disease risk; therefore, although RCTs provide important information on the efficacy and safety of pharmacological agents, the strict inclusion and exclusion criteria and the specialized research facilities and activities often do not reflect the real‐world clinical settings in which the medications are ultimately used. Real‐world studies therefore provide important complementary information about effectiveness in clinical practice, may have better external validity, and are likely to be more generalizable and pertinent to clinicians and healthcare‐delivery systems.[13](#dom13345-bib-0013){ref-type="ref"} The design of DELIVER D+ was the same for both cohorts, and the study should therefore provide useful information for decision‐making in the real world.

DELIVER D+ has some limitations, including its retrospective design and that the Predictive Health Intelligence Environment EMR data mostly came from northwest and southern states, so might not be representative of the broader population with T2D in the United States. Further, patients included in the study were early users of second‐generation basal insulin analogues, so their demographic and clinical characteristics might differ from those of basal insulin‐experienced patients in general. Also, diagnoses were based on ICD‐9/ICD‐10 codes; as EMR data may not link the actual diagnosis name, this could have resulted in misclassification. In addition, the database does not provide the date of initial T2D diagnosis. The different prescribing patterns (based on insurance coverage prior to matching \[Table [S2](#dom13345-supitem-0001){ref-type="supplementary-material"}, Supporting Information\]) suggest that upfront medication cost and medication access may be driving some prescription decisions. Further, EMRs only capture medication prescription, not dispensing or consumption. Also, as dosage data were missing in \>90% of the EMRs, dose information could not be addressed in DELIVER D+. However, we hope to be able to include dose information in a future study using linked data sources.

The reason for switching was not available in the EMRs, so selection bias may not be completely excluded after propensity‐score matching. It is possible that patients who switched treatments in the present study probably did so because their diabetes was not sufficiently controlled on their previous regimen. Evidence from a retrospective real‐world EU‐TREAT study with no comparator reported that the major reason for switching to IDeg was fluctuation in blood glucose values.[25](#dom13345-bib-0025){ref-type="ref"} Switchers may also have received further education about the importance of taking their basal insulin as directed, which could have improved their glycaemic control. Although the majority of inpatient/ED hypoglycaemia episodes would probably be captured in the EMRs, it is probable that a significant number of non‐inpatient/ED hypoglycaemia events were not captured. In addition, self‐monitored blood glucose and continuous blood glucose monitoring data were not available, so the treatment effect on hypoglycaemia could have been underestimated.

Another limitation was the relatively short follow‐up (≤6 months), although this was the same as for the primary endpoint of the EDITION trials,[27](#dom13345-bib-0027){ref-type="ref"}, [28](#dom13345-bib-0028){ref-type="ref"}, [29](#dom13345-bib-0029){ref-type="ref"}, [36](#dom13345-bib-0036){ref-type="ref"} but shorter than the BEGIN and DEVOTE trials.[30](#dom13345-bib-0030){ref-type="ref"}, [31](#dom13345-bib-0031){ref-type="ref"} While pooled 12‐month follow‐up data from EDITION 1, 2 and 3 are now available (showing that Gla‐300 provided more sustained glycaemic control and significantly lower confirmed/severe hypoglycaemia risk compared with Gla‐100),[37](#dom13345-bib-0037){ref-type="ref"} further long‐term data for the second‐generation basal insulin analogues would be beneficial. It is noteworthy, however, that the various limitations relevant to EMRs apply to both cohorts and, therefore, may not significantly impact the overall conclusions of the comparisons of the two basal insulins.

In conclusion, the present study provides complementary findings that support results from RCTs and reflect effectiveness in real‐world clinical practice. In nearly 1600 patients with T2D, switching from a first‐generation (Gla‐100 or IDet) to a second‐generation (Gla‐300 or IDeg) basal insulin analogue resulted in similar improvements in glycaemic control, and in \>3000 patients, switching to Gla‐300 had a similar or better effect on hypoglycaemia compared with IDeg. The subgroup analyses confirmed the overall findings in various patient subgroups of interest. From the perspective of patients and healthcare practitioners, the benefits associated with these newer basal insulin analogues may lead to improved adherence and quality of care; from the perspective of the integrated delivery networks and healthcare systems, they could provide cost savings by reducing hypoglycaemia‐related healthcare resource utilization.
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